Anti-placental growth factor reduces bone metastasis by blocking tumor cell engraftment and osteoclast differentiation

Lieve Coenegrachts, Christa Maes, Sophie Torrekens, Riet Van Looveren, Massimiliano Mazzone, Theresa A. Guise, Roger Bouillon, Jean Marie Stassen, Peter Carmeliet, Geert Carmeliet

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Treatment of bone metastases is largely symptomatic and is still an unmet medical need. Current therapies mainly target the late phase of tumor-induced osteoclast activation and hereby inhibit further metastatic growth. This treatment method is, however, less effective in preventing initial tumor engraftment, a process that is supposed to depend on the bone microenvironment. We explored whether bone-derived placental growth factor (PlGF), a homologue of vascular endothelial growth factor-A, regulates osteolytic metastasis. Osteogenic cells secrete PlGF, the expression of which is enhanced by bone-metastasizing breast tumor cells. Selective neutralization of host-derived PlGF by anti-mouse PlGF (αPlGF) reduced the incidence, number, and size of bone metastases, and preserved bone mass. αPlGF did not affect metastatic tumor angiogenesis but inhibited osteoclast formation by preventing the upregulation of the osteoclastogenic cytokine receptor activator of NF-κB ligand in osteogenic cells, as well as by blocking the autocrine osteoclastogenic activity of PlGF. áPlGF also reduced the engraftment of tumor cells in the bone and inhibited their interaction with matrix components in the metastatic niche. αPlGF therefore inhibits not only the progression of metastasis but also the settlement of tumor in the bone. These findings identify novel properties of PlGF and suggest that αPlGF might offer opportunities for adjuvant therapy of bone metastasis.

Original languageEnglish (US)
Pages (from-to)6537-6547
Number of pages11
JournalCancer Research
Volume70
Issue number16
DOIs
StatePublished - Aug 15 2010

Fingerprint

Osteoclasts
Intercellular Signaling Peptides and Proteins
Neoplasm Metastasis
Bone and Bones
Neoplasms
Cytokine Receptors
Vascular Endothelial Growth Factor A
Up-Regulation
Breast Neoplasms
Ligands

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Anti-placental growth factor reduces bone metastasis by blocking tumor cell engraftment and osteoclast differentiation. / Coenegrachts, Lieve; Maes, Christa; Torrekens, Sophie; Van Looveren, Riet; Mazzone, Massimiliano; Guise, Theresa A.; Bouillon, Roger; Stassen, Jean Marie; Carmeliet, Peter; Carmeliet, Geert.

In: Cancer Research, Vol. 70, No. 16, 15.08.2010, p. 6537-6547.

Research output: Contribution to journalArticle

Coenegrachts, L, Maes, C, Torrekens, S, Van Looveren, R, Mazzone, M, Guise, TA, Bouillon, R, Stassen, JM, Carmeliet, P & Carmeliet, G 2010, 'Anti-placental growth factor reduces bone metastasis by blocking tumor cell engraftment and osteoclast differentiation', Cancer Research, vol. 70, no. 16, pp. 6537-6547. https://doi.org/10.1158/0008-5472.CAN-09-4092
Coenegrachts, Lieve ; Maes, Christa ; Torrekens, Sophie ; Van Looveren, Riet ; Mazzone, Massimiliano ; Guise, Theresa A. ; Bouillon, Roger ; Stassen, Jean Marie ; Carmeliet, Peter ; Carmeliet, Geert. / Anti-placental growth factor reduces bone metastasis by blocking tumor cell engraftment and osteoclast differentiation. In: Cancer Research. 2010 ; Vol. 70, No. 16. pp. 6537-6547.
@article{8ad4934ced1a4b0eb90b41f289404adf,
title = "Anti-placental growth factor reduces bone metastasis by blocking tumor cell engraftment and osteoclast differentiation",
abstract = "Treatment of bone metastases is largely symptomatic and is still an unmet medical need. Current therapies mainly target the late phase of tumor-induced osteoclast activation and hereby inhibit further metastatic growth. This treatment method is, however, less effective in preventing initial tumor engraftment, a process that is supposed to depend on the bone microenvironment. We explored whether bone-derived placental growth factor (PlGF), a homologue of vascular endothelial growth factor-A, regulates osteolytic metastasis. Osteogenic cells secrete PlGF, the expression of which is enhanced by bone-metastasizing breast tumor cells. Selective neutralization of host-derived PlGF by anti-mouse PlGF (αPlGF) reduced the incidence, number, and size of bone metastases, and preserved bone mass. αPlGF did not affect metastatic tumor angiogenesis but inhibited osteoclast formation by preventing the upregulation of the osteoclastogenic cytokine receptor activator of NF-κB ligand in osteogenic cells, as well as by blocking the autocrine osteoclastogenic activity of PlGF. {\'a}PlGF also reduced the engraftment of tumor cells in the bone and inhibited their interaction with matrix components in the metastatic niche. αPlGF therefore inhibits not only the progression of metastasis but also the settlement of tumor in the bone. These findings identify novel properties of PlGF and suggest that αPlGF might offer opportunities for adjuvant therapy of bone metastasis.",
author = "Lieve Coenegrachts and Christa Maes and Sophie Torrekens and {Van Looveren}, Riet and Massimiliano Mazzone and Guise, {Theresa A.} and Roger Bouillon and Stassen, {Jean Marie} and Peter Carmeliet and Geert Carmeliet",
year = "2010",
month = "8",
day = "15",
doi = "10.1158/0008-5472.CAN-09-4092",
language = "English (US)",
volume = "70",
pages = "6537--6547",
journal = "Cancer Research",
issn = "0008-5472",
number = "16",

}

TY - JOUR

T1 - Anti-placental growth factor reduces bone metastasis by blocking tumor cell engraftment and osteoclast differentiation

AU - Coenegrachts, Lieve

AU - Maes, Christa

AU - Torrekens, Sophie

AU - Van Looveren, Riet

AU - Mazzone, Massimiliano

AU - Guise, Theresa A.

AU - Bouillon, Roger

AU - Stassen, Jean Marie

AU - Carmeliet, Peter

AU - Carmeliet, Geert

PY - 2010/8/15

Y1 - 2010/8/15

N2 - Treatment of bone metastases is largely symptomatic and is still an unmet medical need. Current therapies mainly target the late phase of tumor-induced osteoclast activation and hereby inhibit further metastatic growth. This treatment method is, however, less effective in preventing initial tumor engraftment, a process that is supposed to depend on the bone microenvironment. We explored whether bone-derived placental growth factor (PlGF), a homologue of vascular endothelial growth factor-A, regulates osteolytic metastasis. Osteogenic cells secrete PlGF, the expression of which is enhanced by bone-metastasizing breast tumor cells. Selective neutralization of host-derived PlGF by anti-mouse PlGF (αPlGF) reduced the incidence, number, and size of bone metastases, and preserved bone mass. αPlGF did not affect metastatic tumor angiogenesis but inhibited osteoclast formation by preventing the upregulation of the osteoclastogenic cytokine receptor activator of NF-κB ligand in osteogenic cells, as well as by blocking the autocrine osteoclastogenic activity of PlGF. áPlGF also reduced the engraftment of tumor cells in the bone and inhibited their interaction with matrix components in the metastatic niche. αPlGF therefore inhibits not only the progression of metastasis but also the settlement of tumor in the bone. These findings identify novel properties of PlGF and suggest that αPlGF might offer opportunities for adjuvant therapy of bone metastasis.

AB - Treatment of bone metastases is largely symptomatic and is still an unmet medical need. Current therapies mainly target the late phase of tumor-induced osteoclast activation and hereby inhibit further metastatic growth. This treatment method is, however, less effective in preventing initial tumor engraftment, a process that is supposed to depend on the bone microenvironment. We explored whether bone-derived placental growth factor (PlGF), a homologue of vascular endothelial growth factor-A, regulates osteolytic metastasis. Osteogenic cells secrete PlGF, the expression of which is enhanced by bone-metastasizing breast tumor cells. Selective neutralization of host-derived PlGF by anti-mouse PlGF (αPlGF) reduced the incidence, number, and size of bone metastases, and preserved bone mass. αPlGF did not affect metastatic tumor angiogenesis but inhibited osteoclast formation by preventing the upregulation of the osteoclastogenic cytokine receptor activator of NF-κB ligand in osteogenic cells, as well as by blocking the autocrine osteoclastogenic activity of PlGF. áPlGF also reduced the engraftment of tumor cells in the bone and inhibited their interaction with matrix components in the metastatic niche. αPlGF therefore inhibits not only the progression of metastasis but also the settlement of tumor in the bone. These findings identify novel properties of PlGF and suggest that αPlGF might offer opportunities for adjuvant therapy of bone metastasis.

UR - http://www.scopus.com/inward/record.url?scp=77955744282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955744282&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-09-4092

DO - 10.1158/0008-5472.CAN-09-4092

M3 - Article

C2 - 20682798

AN - SCOPUS:77955744282

VL - 70

SP - 6537

EP - 6547

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 16

ER -